Kornimate/medical-research-clean huggingface dataset:
to explore the benefits of the monalisa touch® system in gynaecological cancer patients treated by (chemo)-rt

Conditions: Gynecologic Cancer

Summary: the increasing survival rate of gynaecological cancer patients highlights the need to improve their quality of life (qol) after treatment. among all qol factors, sexuality is unfortunately often neglected, especially vaginal dryness and fibrosis/stenosis. currently, the latter is standardly treated by vaginal dilators, which may induce pain and discomfort (1). a new possibility, already used in some centers, is the monalisa touch® system, a microablative co2 laser (2). its efficiency to improve sexual qol has already been demonstrated in breast cancer patients treated with chemotherapy and/or hormonotherapy and in menopausal women (3). unfortunately, almost no study have been conducted yet for patients undergoing radiotherapy to the pelvic area to prevent vaginal morbidity. our randomised study will explore the benefits of the monalisa touch® device for the prevention of sexual adverse events induced by pelvic (chemo-) radiotherapy for pelvic cancers.

patients will be randomly (1:1) assigned to the dilators (standard of care) or monalisa touch® system (2 arms). patients will be stratified for endometrial or cervix cancer, radiotherapy dose and techniques, menopausal status, tumor stage, chemotherapy or not, surgery or not. patients will begin the mona lisa at 3 months, once per month during 6 months while the follow-up assessment will continue until 12m after end of rt treatment. patients randomized in dilator arm will also begin 3 months post end of rt and will use them twice every 2 weeks for 12m (as standard of care). questionnaires (fsfi- female sexual function index \[10\], shq-22) and vhi (vaginal health index \[11\]) will be performed before treatment, at 3, 6, 9, 12 and 15m. partners will also be asked to fill the sexual quality of life questionnaire eortc shq-22 before and after treatment.

Eligibility criteria:
inclusion criteria: * (chemo)radiotherapy +/- brachytherapy, gynaecologic cancer patients * complete response on the imagery at 3 months (pet scan/mri). * stades i-iii exclusion criteria: * m1 * stade iv * no complete response under imagery at 3months * relapse of gynaecological cancer * active gynaecological infection * pelvic organ prolapse more than stage ii * local vaginal hormone therapy within 6 weeks prior to enrolment
peppermint oil pharmacokinetics/dynamics

Conditions: Abdominal Pain

Summary: in children 7-12 years of age with functional abdominal pain (n=42) determine: aim 1 - to examine and characterize the threshold of the exposure (pk) vs. response (pd) relationship of pmo (menthol) aim 2 - pd of pmo as assessed by: 1. microbiome composition (16s rna sequencing) 2. transit rate/contractile activity (using the smartpill®) aim 3 - evaluate the potential association between pd response and clinical symptoms (abdominal pain and stooling pattern via validated diary), psychosocial distress (anxiety, depression, somatization), and characterize potential side effects (questionnaire)

an initial single-dose pk study will be carried out. forty-two children (n=21 per dose) will be randomized to receive approximately 10.9 mg·kg-1·d-1 of pmo or to receive approximately 18.2 mg·kg-1·d-1 (1.67-fold the median dose). following the single-dose pk study, a pd study will be carried out wherein the subjects will receive their assigned dose of pmo for 7 days. at baseline (before the pk study) and after the pk study (i.e., during the pd study), subjects will keep a pain and stooling diary, collect stool for microbiome analysis, and swallow a smartpill to measure gut motility and transit time. at baseline only, anxiety, depression, somatization will be measured. during the pd study, any side effects will be recorded.

Eligibility criteria:
inclusion criteria: * children ages 7-12 years who are able to assent to the procedures * able to complete the diaries which have been validated for use in this age range * the history and medical evaluation reveal no organic reason for the abdominal pain * the child has abdominal pain that meets the definition of fap according to pediatric rome iv * ability to understand study procedures and to comply with them for the entire length of the study * childrens' body weights will not vary by more than 10-15 kg (so that dose per kg is comparable within the two dosing groups) exclusion criteria: * past bowel surgery * documented gi disorders (e.g., crohn's disease) * a serious chronic medical condition (e.g., diabetes) * a weight and/or height \< 2 sd for age * chronic conditions with gi symptoms (e.g., cystic fibrosis) * autism spectrum disorder, significant developmental delay, psychosis, depression, or a history of bipolar disorder * antibiotic/probiotic treatment within 2 mo. * allergy/sensitivity to pmo or its ingredients * inability to swallow the pmo capsule or the smartpill® * inability to speak english - testing materials are available only in this language * unable to discontinue laxative, prokinetic, or neuromodulator from 3 wk prior to visit 1 through the end of the study
influence of roxolid implant material on the implant stability implant stability

Conditions: Completely Edentulous Patients

Summary: fourteen completely edentulous patients were selected to participate in this study. from the outpatient clinic of prosthodontic department, faculty of dentistry, ain shams university. after fabrication of complete denture for all patients, patients were randomly divided to: group a: seven patients were rehabilitated with implant retained maxillary overdenture where four straumann blx® implant were inserted opposed by mandibular complete denture. group b: seven patients were rehabilitated with implant retained maxillary overdenture where four conventional acid etched implants were inserted opposed by mandibular complete denture. after implant placement using surgical guide, smart peg and ostell device were used to measure the primary stability of the implant then cover screw was placed and after six weeks, secondary stability was measured for both groups. after four months, the second stage started in which exposure of the implant fixtures took place and pick up was carried out. patients were recalled frequently for post-insertion inspection and adjustment.

background: long term success of implant restoration depends on many factors one of them is the sufficient implant stability which is lowered in compromised bone density sites such as the maxilla which is categorized as type iii \& iv bone, so searching for new innovation and updates in implant material and features is very mandatory. so, the aim of this study was asses and compare between two implant materials roxolid versus traditional titanium on the primary and secondary stability. methods: eighteen completely edentulous patients were selected they all received maxillary implant retained overdentures and lower complete dentures, they were divided equally in to two groups according to the type of the material of the implants. group a received a total number of 36 (roxolid) implants were made of roxolid material and group b received a total number 36 (titanium) implants were made of traditional titanium alloys. implant stability was assed using ostell device, the primary implant stability was measured at the day of implant installation however, secondary implant stability was measured after six weeks of implant placement. paired t-test was used to compare between primary and secondary stability in the same group and independent t-test was used to compare between the two groups with a significant level \< 0.05.

Eligibility criteria:
inclusion criteria: * completely edentulous patients as the last extraction should be at least six months before implant placement. * patients with good oral hygiene. * sufficient inter arch space (11 mm) which were diagnosed by mounted diagnostic casts. * firm and healthy mucosa covering the residual alveolar ridge. exclusion criteria: * - heavy smokers. * patients with para functional habits. * patients had tmj disorders. * patients had systemic disease that could interfere with implant placement or affect bone healing such as; thyroid and uncontrolled diabetes. * patients undergoing chemo and radiotherapy.
the effects of low intensity training with blood flow restriction in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) patients showed systemic manifestations that may lead to a reduction in muscle strength, muscle mass and, consequently, to a reduction in physical function. on the other hand, high intensity resistance training (hirt) are able to improve muscle strength and muscle mass in ra without affecting the disease course. however, due to the articular manifestations caused by this disease, these patients may present intolerance to hirt. thus, the low intensity resistance training with blood flow restriction (tbfr) may be a new training strategy for these populations. in this sense, the investigators speculate that tbfr could be beneficial in ra patients, as well as, hirt.


Eligibility criteria:
inclusion criteria: * female; * rheumatoid arthritis patients; * all individuals will undergo an ergospirometry to ensure cardiorespiratory conditions. exclusion criteria: * fibromyalgia; * cardiovascular disease;

Keywords: rheumatoid arthritis kaatsu blood flow restriction training
factors influencing risk of progression of chronic kidney disease

Conditions: Chronic Kidney Disease stage4

Summary: the aim of this study is to identify typical patterns of renal function evolution in patients with stage 4 chronic kidney disease, regularly followed in nephrology consultation and included in a french cohort.


Eligibility criteria:
inclusion criteria: * patients meeting the inclusion criteria of the nd-cris cohort (long-term follow-up in one of the centers participating in the research, with a gfr \<60ml/min /1.73m2) * patients included in the nd-cris cohort on the date when the estimate of their gfr is strictly less than 30ml/min/1.73m2 and greater than or equal to 15ml/min/1.73m2 (mdrd equation). patients should have at least two measurements of gfr \<30ml/min/1.73m2 to be included, at least one of them greater than or equal to 15ml/min/1.73m2. the date of the first gfr \<30ml/min/ 1.73m2 will be considered as the date of origin. exclusion criteria: * patients with gfr ≥30ml / min / 1.73m2 or \<15ml / min / 1.73m2 * patients who do not meet the inclusion criteria of nd-cris cohort (dialysis patients, transplant patients, unfollowed patients)
comparison of clinical efficacy between dynamic dip screw and cannulated compression screw for fresh femoral neck fracture

Conditions: Femoral Neck Fractures

Summary: for fresh femoral neck fracture internal fixation, both dhs and ccs can make strong fixation of hip and have good recovery. there is no statistical difference in complications after surgery between the two procedures. patients with dhs internal fixation have earlier postoperative weight bearing, which is conducive to functional exercise of the injured limb. dhs internal fixation system is recommended for patients with unstable fractures and severe osteoporosis.

objective: to compare the clinical effect of dynamic hip screw (dhs) and cannulated compression screw (ccs) in the treatment of fresh femoral neck fracture. methods: a retrospective study was conducted to analyze the data of 91 patients with fresh femoral neck fracture treated with dhs or ccs in our hospital from january 2012 to june 2016.the cases were divided into two groups according to internal fixation: 44 cases in the dhs group and 47 cases in the ccs group. by comparing operative time, intraoperative bleeding, postoperative load, harris scoring and the complications such as postoperative necrosis of femoral head and shortening of femoral neck appearance, we evaluated the clinical curative effect of two kinds of fixation.

Eligibility criteria:
inclusion criteria: * fresh femoral neck fracture * can walk before fracture * less than 65 years old exclusion criteria: * patients combined with other bone fractures. * pathological fracture (e.g., primary or metastatic tumor) * serious soft tissue injury, judged by the investigator, will impact the union of the fracture, combined open fractures, vascular injury, and combined osteofascial compartment syndrome. * multiple systemic injuries judged by researchers not suitable for enrollment. revision surgeries (for example, due to malunion, nonunion or infection) * concurrent medical conditions judged by researchers not suitable for enrollment, such as: metabolic bone disease, post-polio syndrome, poor bone quality, prior history of poor fracture healing, etc * patients known to be allergic to implant components * patients who are currently using chemotherapeutics or accepting radiotherapy, use systematically corticosteroid hormone or growth factor, or long-term use sedative hypnotics (continuous use over 3 months) or non-steroidal anti-inflammatory drugs (continuous use over 3 months) * subjects have significant neurological or musculoskeletal disorders or may have adverse effects on gait or weight-bearing (e.g., muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, charcot arthropathy, avascular necrosis of the femoral head).

Keywords: femoral neck fracture internal fixation of fracture dynamic hip screw cannulated compression screw
effects of echo-optimization of left ventricular assist devices on functional capacity (vafract)

Conditions: Heart Failure

Summary: after the implantation of a left ventricular assist device (lvad), many patients continue to experience exercise intolerance. lvad echo guided optimization (eo) determines a more favorable hemodynamic profile and could provide an improvement on functional capacity (fc). vafract is a prospective randomized trial to evaluate the additional benefit of an eo approach on fc, measured by cardiopulmonary exercise test (cpet), in lvad optimization free population.

the use of left ventricular assist devices (lvad) is a viable therapeutic option to improve survival and quality of life of patients with advanced and refractory heart failure (hf). however, after the implantation of an lvad, patients' functional capacity (fc) is still reduced with maximum oxygen uptake (vo2 peak) values calculated at the cardiopulmonary exercise test (cpet) ranging from 11 to 20 ml/kg/min. lvad echo guided optimization (eo) determines a more favorable hemodynamic profile, in particular for the right ventricle, and could provide an improvement on fc. vafract is a prospective randomized trial to evaluate the additional benefit of an eo approach on fc, measured by cpet in lvad optimization free population. the optimal device speed is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation associated or not to a dilatation of the right ventricle (rv). in this condition it is reasonable to expect a more favorable hemodynamic profile for the rv and a better response in terms of functional capacity. subjects studied are hf patients supported with a continuous-flow lvad: heartmate ii (thoratec inc., pleasanton, ca) and heartmate 3 (hm 3, abbott, north chicago, il). patients are recruited from our day hospital of the cardiac surgery department at the university hospital of verona.

Eligibility criteria:
inclusion criteria: * at least 3 months after lvad implantation; * compliance to the required follow-up schedule; * age 18 or above or of legal age to give informed consent specific to state and national laws. exclusion criteria: * distance of less than 150 meters on the six-minute walk test (6mwt) or impossibility to perform cpet * recent finding of any major device-related complication (sepsis, thrombosis ...).

Keywords: left ventricular assist device echo-optimization functional capacity cardiopulmonary exercise test
effect of nebulized budesonide on preventing postextubation complications in critically patients

Conditions: Respiratory Sounds

Summary: the aim of this study is evaluation of the effect of administration nebulized budesonide after extubation. the specific objectives of our study are to determine whether multiple doses of nebulized budesonide are effective to reduce or prevent postextubation edema. in this double-blind randomized clinical trial study, 70 patients (age between 18 to 65) who are intubated (at least for 48 hours) and now are ready for extubation will be enrolled in the study after obtaining a written informed consent from their parents or guardians. the investigators divide our patients randomly into two equal groups. -patients who are in budesonide group will receive nebulized budesonide (1 mg-every 12 hours; n=35) and patients in placebo group receive placebo (normal saline; n=35) until 48 hours after extubation. if patient have extubation criteria the investigators will extubate him and for 24 hours after, another anesthesiologist who is unaware about kind of medication, will evaluate the patients for severity of stridor. we will record the vital sings and grade of stridor every 6 hour. respiratory rate (rr), heart rate (hr), blood pressure (bp) and oxygen saturation (spo2) were recorded for each patient immediately before aerosol administration (time 0) and at 30 and 60 min; and 2,4,8,12,24,36 and 48 hrs. after extubation then the presence of stridor (heard with the aid of stethoscope) was recorded within 48 hr of extubation.


Eligibility criteria:
inclusion criteria: 1. patients' age 18-55 years old 2. intubated for more than 48 hours after surgery 3. met the weaning criteria defined as respiratory rate \ 5 ml/kg ideal body weight, and shallow index (respiratory rate/tidal volume) \< 105 breaths / min/l exclusion criteria: 1. any history of corticosteroid therapy in previous week 2. nasal or throat disease / surgery 3. pulmonary airway disease 4. gastrointestinal bleeding
cognitive modulation of dyspeptic symptom during food ingestion in functional dyspepsia patients cognitive modulation

Conditions: Brain Imaging; Functional Dyspepsia; Food

Summary: in this functional magnetic resonance imaging study, effects of different information of fat content of high or low fat will be examined in fd patients and healthy volunteers (n=30, respectively). these data will provide a better understanding of symptom generation following food ingestion in general as well as in patients with respective functional gastrointestinal disorders.


Eligibility criteria:
inclusion criteria: * male and female, volunteering adults bmi: 18-25 kg/m² right-handed age: 18-65 years capacity to give informed consent for fd patients, diagnosis of functional dyspepsia over the last 12 months certified by a medical record inconspicuous gastroscopy during the last 6 months certified by a medical record exclusion criteria: * subjects which have a non-removable metal object in or at their body, such as, for example: * heart pace-maker, * artificial heart valve, * metal prosthesis, * metallic implants (screws, plates from operations, etc.), * interuterine spiral, * metalsplinters / grenade fragments * non-removable dental braces, * acupuncture needles, * insulin pump, * intraport, etc., pregnant women or pregnancy cannot be excluded nursing women subjects with limited temperature perception and/or increased sensitivity to warming of the body a circulatory disease cannot be excluded subjects with hearing-disease or an increased sensitivity to loud noises subjects with fear of closed-in places (claustrophobia) subjects which were operated less than three month ago acute illness or infection neurological disorder or injury (e.g. epilepsy) moderate or severe head injury severe psychotic illness (e.g. schizophrenia, depression) intake of antidepressants / antipsychotics vegetarians/vegans food allergies self-reported eating disorder
a proposal for a new classification of secondary cleft lip and nose deformities in repaired unilateral cleft lip

Conditions: Patients With Unilateral Cleft Lip With or Without Cleft Palate

Summary: congenital cleft lip with or without cleft palate is one of the most common congenital malformations with an estimated incidence of about 1 every 500 to 700 live births. cleft lip and palate are caused by a complex combination of many environmental and genetic factors sharing into the etiology. patients with cleft lip and palate undergo multiple surgeries to reconstruct the anatomy and function to achieve symmetric, aesthetic, and functional nasolabial region. the most important goals of correction of the cleft are to achieve an acceptable facial appearance and psychological and social well-being for the patient and his or her family. therefore, assessment of nasolabial appearance following cleft surgery remains an important parameter for evaluating the outcome of the procedure. unfortunately, some residual deformities in the nasolabial region such as the abnormal shape of the nose, scar of the upper lip, uneven white roll, notched or excess vermilion border will remain noticeable. so, the assessment of secondary cleft nasolabial deformities needs a reliable rating scale. although many scoring systems have been described in the literature, there is no globally accepted reliable one. a frequently used scoring system is the one proposed by asher-mcdade that uses frontal and lateral view masked prints of the nasolabial area. the use of three-dimensional (3d) imaging seems to be the most reliable in assessing cleft-related facial deformities. however, scoring based on two-dimensional (2d) photographs is easier to perform and more applicable in daily practice because all cleft patients are photographed during their treatment journey at predetermined intervals. assessment of secondary nasolabial deformities in cleft patients in large numbers of patients helps compare the aesthetic results of the different treatment protocols and techniques.


Eligibility criteria:
inclusion criteria: all patients with unilateral cleft lip who had undergone primary cleft lip repair surgeries during their first year of life at sohag university hospital from january 2006 to december 2020. exclusion criteria: 1. patients with multiple cleft lip repair surgeries. 2. if the primary cleft lip surgery was performed after the first year of life. 3. patients with no available photographs